Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520305-39-00

Enrollment

Registered

2025-01-21

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cluster headache

Brief summary

Mean change in weekly attack frequency in the third treatment week compared to the 4-week baseline, across treatment groups.

Interventions

DRUGLysergide D-tartrate

DRUGPlacebo for Lysergide tartrate oral solution

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean change in weekly attack frequency in the third treatment week compared to the 4-week baseline, across treatment groups.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026